Pancreatic Cancer Research

ResearcherUniversité Libre de BruxellesActive in the last 2 years

Oier Azurmendi Senar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0004-1658-6111; OpenAlex author ID A5091982381. Sources: OpenAlex.

Their work

Papers
7 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 7

  1. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy. First author DOI 10.1038/s41416-025-03274-0↗
  2. Glycation Stress–Driven Transcriptomic Signature Predicts Survival Benefit from Adjuvant Gemcitabine in Resectable Pancreatic Cancer Co-author DOI 10.1101/2025.07.07.663493↗
  3. Impact of the radiological morphology of the mesopancreas on the outcome after pancreatoduodenectomy for pancreatic ductal adenocarcinoma: retrospective study. Co-author DOI 10.1093/bjsopen/zrae134↗
  4. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Stereotactic Body Radiotherapy First author DOI 10.1101/2024.04.30.591890↗
  5. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma or a Metaphor for Heterogeneity: From Single-Cell Analysis to Whole-Body Imaging. Co-author DOI 10.3390/biomedicines12030591↗
  6. Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response. Co-author DOI 10.3390/cells12101414↗
  7. A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cells13010003↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tatjana Arsenijevic · 7 shared papers, 2023–2026 · strength 1.34
  2. Julie Navez · 6 shared papers, 2023–2026 · strength 1.19
  3. Christelle Bouchart · 6 shared papers, 2023–2026 · strength 1.19
  4. Jean‐Luc Van Laethem · 6 shared papers, 2023–2026 · strength 1.14
  5. Kosta Stosic · 5 shared papers, 2023–2026 · strength 1.00
  6. Pieter Demetter · 4 shared papers, 2024–2026 · strength 0.77
  7. Nicky D’Haene · 4 shared papers, 2023–2026 · strength 0.72
  8. Rémy Nicolle · 3 shared papers, 2024–2026 · strength 0.58
  9. Léo Mas · 2 shared papers, 2024–2026 · strength 0.38
  10. Shulin Zhao · 2 shared papers, 2024–2026 · strength 0.38
  11. Matthieu Hein · 2 shared papers, 2024–2026 · strength 0.38
  12. Ilse Rooman · 2 shared papers, 2024–2026 · strength 0.38
  13. Jean‐Baptiste Bachet · 2 shared papers, 2024–2026 · strength 0.38
  14. Akeila Bellahcène · 2 shared papers, 2023–2025 · strength 0.35
  15. Rebekah Crake · 2 shared papers, 2023–2025 · strength 0.35
  16. Ellis Michiels · 1 shared paper, 2026 · strength 0.22
  17. Rita Saúde-Conde · 1 shared paper, 2024 · strength 0.22
  18. Jean-Luc Van-Laethem · 1 shared paper, 2025 · strength 0.20
  19. Thierry Conroy · 1 shared paper, 2025 · strength 0.20
  20. Jerome F. Cros · 1 shared paper, 2025 · strength 0.20
  21. Jean Closset · 1 shared paper, 2024 · strength 0.19
  22. Maria Antonietta Bali · 1 shared paper, 2024 · strength 0.19
  23. Marie-Lucie Racu · 1 shared paper, 2024 · strength 0.19
  24. Jacques M.E. Deviere · 1 shared paper, 2024 · strength 0.19
  25. Raphaël Peiffer · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.